MYC and hematopoietic and lymphoid system neoplasm: For example, MLL-rearranged leukemias with PRC2 loss, either pre-existing or acquired, are resistant to BRDi presumably due to enhanced transcription of oncogenes such as MYC (129); furthermore, recent reports documented acquisition of somatic mutation by blood cancer cells during resistance to BRDi or EZHi (129, 130).